A dvances in modern medicine have had a profound effect on cardiovascular disease (CVD) and its manifestations. As the age-adjusted mortality of CVD has dropped, new challenges have emerged (1,2). The prevalence and disability associated with CVD are rising because of the aging population and the obesity epidemic (3). Hospital discharges attributable to CVD have also increased over time (4). Many more patients survive previously lifethreatening events such as acute myocardial infarction, but they live with heart failure (HF), which is expected to rise in prevalence to more than 8 million (6, 7) . Neither study found an improvement in overall survival, which could be mediated by this changing underlying etiology. The reduction in shockable rhythms as a proportion of cardiac arrests has also been noted among inpatients (8, 9) .
Patients with HF comprise one of the groups at highest risk for SCD. However, increased use of medical therapy has led to a 44% reduction in SCD in patients with HF, according to a recent study analyzing 12 clinical trials from 1995 through 2014 (10) . This changing mode of death, from SCD to pump failure, is one of the reasons that death and dying have become protracted processes dominating the final years of life of patients with advanced CVD (11) .
DISABILITY, COMORBIDITY, AND POLYPHARMACY IN THE LAST YEARS OF LIFE
The past 150 years have seen the most dramatic increase in average life expectancy and maximum life span in human history, with a reduction in age-adjusted mortality for CVD across all age groups (4,12). This success in life span extension, coupled with reductions in fertility rates, has transformed the traditionally pyramidal distribution of the human population into a rectangle (13) . Even in the emerging economy of China, by the year 2050, there will be 500 million people older than 60 years of age, accounting for almost one-half the population of that country (14) .
Although it had been hypothesized that the same advances that extend life span would also delay the onset of chronic disease, longitudinal data have shown no evidence of such "morbidity compression" (15) (16) (17) . Factors throughout the span of life influence the extent and duration of disability patients live with ( Figure 1 ). In fact, younger U.S. cohorts now entering older age appear to have increased disability compared with prior groups, a trend driven by poor health in middle age, promoted by factors such as smoking and obesity (18) . Therefore, despite greater mean life expectancy, disability-free life among older Americans is similar to that of low-income countries such as Mexico and Costa Rica (19) .
Several groups are more likely to experience disability than others. Women have a longer life span than men, but they also spend a greater amount of time living with disability, and this difference increases over time (20) . This phenomenon has been referred to as the male-female morbidity-mortality paradox. Older blacks also experience fewer disabilityfree years than whites, with this disparity particularly pronounced for black women (21) .
Medical comorbidities are significant drivers of disability at the end of life for patients with CVD. Chronic disorders, such as hypertension and diabetes, frequently cluster in patients with CVD, and the prevalence of these comorbidities increases with age (22) .
The increasing burden of medical comorbidities with age is accompanied by rising rates of polypharmacy. The average number of medications taken in a trial of terminally ill patients (mean survival 265 days) was 12.5 (23) . Notably, no reduction was noted in average medications as patients approached death.
The combination of disability, comorbidity, and polypharmacy frequently progresses to frailty, a syndrome that increases vulnerability to even minor stressors with reduced physiological reserves (18) . 
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How Medicine Changed the End of Life are more likely to die in a hospital than at home (62, 63) . Even individuals who do not belong to an ethnic minority are more likely to die in a hospital if they live in a neighborhood with a large minority population (64) . This difference has also widened with time (65-67).
Modern medicine has created an increased need for palliative approaches to complex decision making and withdrawal of medical therapies. Yet palliative care is underused in minority populations, and this is a major driver of disparities at the end of life. Fewer
African Americans and Hispanics with CVD die in hospice compared with whites ( Figures 3A and 3B ).
Minorities are also less likely even to use hospice services or sign an advance directive compared with whites (68-70). In patients with HF, nonwhite race is associated with lower use of palliative care and hospice services (71) . Conversely, minorities are much more likely than whites to use intensive care and invasive procedures at the end of life, with the result that African Americans and Hispanics accrue 32% and 57% more health care costs, respectively, than matched whites in the last 6 months of life (72) .
CAREGIVER BURDEN AND ITS IMPLICATIONS

Informal caregiving is provided by 1 in 4 adult
Americans, and most of these caregivers are women (73, 74) . They account for 90% of home care delivered, providing upward of $450 billion dollars in services, and spending an average of 20 h a week providing these services (73, 74) . As a result, one-fifth of care-
givers lose employment and one-third lose most or all of their savings because of their responsibilities (75) . The emergence of durable mechanical circulatory support has created an entirely new type of caregiver demand. Caregiving for patients discharged to home with LVADs is more burdensome than the care of heart transplant candidates or recipients (96) , and it was found to be comparable in burden to patients receiving mechanical ventilation at home in 1 study (97) . Caregivers of patients with LVADs exhibit a very high prevalence of depression at discharge (78%), although this improves over time (33% at 3 months post-discharge) (98 The fundamental ethical principle of autonomy, however, allows patients to discontinue even lifesaving therapy, and this principle also applies to patients with permanent pacemakers and LVADs (133) . Shared decision making and a discussion of end-of-life considerations is therefore particularly important when discussing implantation of durable cardiac devices.
UNMET NEEDS FOR PALLIATIVE CARE IN CVD
Palliative care is a "multidisciplinary approach to care
that focuses on quality of life and a good death" (134) Warraich et al.
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An inability to prognosticate accurately is a major impediment to the appropriate application of palliative care to patients. 36. van der Plas AG, Oosterveld-Vlug MG, Pasman HR, Onwuteaka-Philipsen BD. Relating cause of death with place of care and healthcare costs in the last year of life for patients who died from cancer, chronic obstructive pulmonary disease, heart failure and dementia: a descriptive study using registry data. Palliat Med 2017;31: 338-45. Dynamic preferences for site of death among patients with advanced chronic obstructive pulmonary disease, chronic heart failure, or chronic renal failure. J Pain Symptom Manage 2013;46:826-36.
OVERCOMING CHALLENGES IN END-OF-LIFE CARE FOR PATIENTS WITH CVD
OPTIMIZE
